Real-world characteristics, treatment patterns, and outcomes of patients with mantle cell lymphoma by line of therapy
Outcomes of patients who received 2 L+ for MCL remain poor, highlighting unmet need in the contemporary treatment paradigm.
Authors
- Ching-Kun Wang
- Enrico De Nigris
- Helmneh M. Sineshaw (ORCID: https://orcid.org/0000-0001-6926-7895)
- Jennifer Prescott (ORCID: https://orcid.org/0000-0002-5703-8953)
- Uzor C. Ogbu (ORCID: https://orcid.org/0000-0002-6438-9110)
- Claire Bai
- Christina M. Zettler (ORCID: https://orcid.org/0000-0002-7516-593X)
- Laura L. Fernandes (ORCID: https://orcid.org/0000-0002-5986-3885)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Merck Serono Ltd. (United Kingdom) (GB)
- MSD (UK) Limited (United Kingdom) (GB)
- New York State PTA (US)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-10-03
- DOI
- https://doi.org/10.1080/14796694.2025.2565829
- Citations
- 1
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.47